Shanghai Ambiopharm,Inc.

Founded in 2005, Shanghai Ambiopharm, Inc. is a manufacturer of active pharmaceutical ingredients that specializes in peptide-based APIs, with a product range covering compounds such as triptorelin, vasopressin, pramlintide, bivalirudin, goserelin, nesiritide, octreotide, exenatide, leuprolide and eptifibatide. Operating from its Shanghai Chemical Industry Park site in Fengxian District, the company works as a peptide contract development and manufacturing organization (CDMO), offering CRO and CDMO services and supporting production at scales spanning bulk peptides to custom specifications through both solid- and solution-phase chemistry. It has recently expanded its Shanghai manufacturing facility with additional GMP production lines to strengthen large-scale and late-stage manufacturing capacity, integrating with its U.S. operations for efficient technology transfer. Competitive strengths cited include internationally certified production, experienced R&D personnel, and a willingness to accommodate buyers' specification requirements, and the company sells into North America, Western and Eastern Europe, Australasia, Asia, Central/South America, the Middle East and Africa.